Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Sharing CAR T-cell data: an EBMT perspective

Jürgen Kuball • 12 Oct 2020
EBMT 2020
General CAR-T

Jürgen Kuball, MD, PhD, Utrecht University, Utrecht University, Netherlands, discusses the European Blood and Marrow Transplantation (EBMT) perspective on the importance of sharing CAR-T cell data. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jürgen Kuball

The role of post-transplant DLI to eradicate MRD in leukemia
0:55
The role of post-transplant DLI to eradicate MRD in leukemia
Jürgen Kuball • 13 Feb 2026
Building alignment in CAR-T data collection using a Delphi survey
1:10
Building alignment in CAR-T data collection using a Delphi survey
Jürgen Kuball • 13 Feb 2026
The launch of the CAR-T Passport for Physicians: an update on the work of the GoCART coalition
1:16
The launch of the CAR-T Passport for Physicians: an update on the work of the GoCART coalition
Jürgen Kuball • 13 Feb 2026
Dual targeting of the cancer metabolome & stress antigens to improve efficacy of engineered T-cells
1:12
Dual targeting of the cancer metabolome & stress antigens to improve efficacy of engineered T-cells
Jürgen Kuball • 17 Feb 2024

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals